Fujitsu和DT-Axis伙伴加速日本的SAMD发展,为AI健康应用程序提供一个共享平台。 Fujitsu and DT-Axis partner to speed SaMD development in Japan with a shared platform for AI health apps.

Fujitsu和DT-Axis合作在日本加快软件作为医疗装置的开发和商业化,旨在简化AI驱动诊断和治疗应用程序的监管批准、系统设计和市场后操作。 Fujitsu and DT-Axis have partnered to accelerate the development and commercialization of Software as Medical Device (SaMD) in Japan, aiming to streamline regulatory approval, system design, and post-market operations for AI-driven diagnostics and therapeutic apps. 根据一项谅解备忘录,这些公司将支持研究机构、医疗装置公司和在保健系统发展、安全的数据管理和遵守规章方面拥有专门知识的制药公司。 Under a memorandum of understanding, the companies will support research institutions, medical device firms, and pharmaceutical companies with expertise in healthcare system development, secure data management, and regulatory compliance. 合作包括计划建立一个萨马德分配平台,形成一站式生态系统,以提高数字保健创新的速度和质量,提高公共保健成果。 The collaboration includes plans to create a SaMD distribution platform, forming a one-stop ecosystem to improve the speed and quality of digital health innovation and enhance public healthcare outcomes.